NLS Pharmaceutics (NASDAQ:NCEL) Director Olivier Samuel Acquires 81,818 Shares

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Director Olivier Samuel acquired 81,818 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $2.75 per share, with a total value of $224,999.50. Following the acquisition, the director directly owned 81,818 shares of the company’s stock, valued at $224,999.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

NLS Pharmaceutics Stock Up 2.1%

Shares of NCEL opened at $3.42 on Thursday. The business has a fifty day moving average of $2.73 and a 200 day moving average of $4.04. NLS Pharmaceutics Ltd. has a one year low of $1.83 and a one year high of $30.80.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.